These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32697585)

  • 1. Spatiotemporally Targeted Nanomedicine Overcomes Hypoxia-Induced Drug Resistance of Tumor Cells after Disrupting Neovasculature.
    Chen J; Jiang Z; Xu W; Sun T; Zhuang X; Ding J; Chen X
    Nano Lett; 2020 Aug; 20(8):6191-6198. PubMed ID: 32697585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
    Yang S; Tang Z; Hu C; Zhang D; Shen N; Yu H; Chen X
    Adv Mater; 2019 Mar; 31(11):e1805955. PubMed ID: 30680816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
    Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
    Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors.
    Deng C; Zhao J; Zhou S; Dong J; Cao J; Gao J; Bai Y; Deng H
    Mol Ther; 2020 Jan; 28(1):75-88. PubMed ID: 31672285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment.
    Shen N; Wu J; Yang C; Yu H; Yang S; Li T; Chen J; Tang Z; Chen X
    Nano Lett; 2019 Nov; 19(11):8021-8031. PubMed ID: 31558024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.
    Iversen AB; Busk M; Horsman MR
    Acta Oncol; 2013 Oct; 52(7):1320-6. PubMed ID: 23988183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate.
    Holmes T; Brown AW; Suggitt M; Shaw LA; Simpson L; Harrity JPA; Tozer GM; Kanthou C
    Sci Rep; 2020 Jun; 10(1):9926. PubMed ID: 32555222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation.
    Liu Y; Wang S; Zhao X; Feng Y; Bormans G; Swinnen J; Oyen R; Huang G; Ni Y; Li Y
    Diagnostics (Basel); 2020 Jan; 10(2):. PubMed ID: 32024029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificial tumor microenvironment regulated by first hemorrhage for enhanced tumor targeting and then occlusion for synergistic bioactivation of hypoxia-sensitive platesomes.
    Tao W; Zhao D; Li G; Li L; Li S; Ye H; Tian C; Lu Y; Li S; Sun Y; He Z; Sun J
    Acta Pharm Sin B; 2022 Mar; 12(3):1487-1499. PubMed ID: 35530142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft.
    Fu XH; Li J; Zou Y; Hong YR; Fu ZX; Huang JJ; Zhang SZ; Zheng S
    Cancer Lett; 2011 Dec; 312(1):109-16. PubMed ID: 21893381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.
    Horsman MR; Wittenborn TR; Nielsen PS; Elming PB
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.
    Dey S; Kumari S; Kalainayakan SP; Campbell J; Ghosh P; Zhou H; FitzGerald KE; Li M; Mason RP; Zhang L; Liu L
    Oncotarget; 2018 Jan; 9(3):4090-4101. PubMed ID: 29423106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.
    Yeung SC; She M; Yang H; Pan J; Sun L; Chaplin D
    J Clin Endocrinol Metab; 2007 Aug; 92(8):2902-9. PubMed ID: 17550961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.
    Welford AF; Biziato D; Coffelt SB; Nucera S; Fisher M; Pucci F; Di Serio C; Naldini L; De Palma M; Tozer GM; Lewis CE
    J Clin Invest; 2011 May; 121(5):1969-73. PubMed ID: 21490397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions.
    Song W; Tang Z; Zhang D; Yu H; Chen X
    Small; 2015 Aug; 11(31):3755-61. PubMed ID: 25919954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development and use of vascular targeted therapy in ovarian cancer.
    Chase DM; Chaplin DJ; Monk BJ
    Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Water-Soluble Combretastatin A4 Phosphate Orally Delivered via Composite Nanoparticles With Improved Inhibition Effect Toward S180 Tumors.
    Shen Y; Wu L; Qiu L
    J Pharm Sci; 2017 Oct; 106(10):3076-3083. PubMed ID: 28619603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour vascular disrupting agents: combating treatment resistance.
    Tozer GM; Kanthou C; Lewis G; Prise VE; Vojnovic B; Hill SA
    Br J Radiol; 2008 Oct; 81 Spec No 1():S12-20. PubMed ID: 18819993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
    Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
    Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.